• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Viramune (nevirapine) (11/9/2000)

The existing labeled warnings for the risk of hepatotoxicity with Viramune treatment have been strengthened in response to continued reports of severe, life-threatening and in some cases, fatal hepatotoxicity that have been reported from clinical trials and postmarketing use with Viramune.

[November 9, 2000 - Health Professional Letter - Boehringer Ingelheim]